跳至主要内容
临床试验/NL-OMON20133
NL-OMON20133已完成不适用

INTENDED

/A0 个研究点目标入组 44 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
44

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Healthy controls:
  • -22 healthy controls 40-70 years, BMI <30kg/m2
  • - 11 controls of Caucasian descent and 11 of Surinamese descent
  • Type 2 Diabetes (T2D) subjects:
  • -22 T2D patients (11 of Caucasian descent and 11 of Surinamese descent)
  • -40-70 years
  • -BMI 25-35
  • -Stable anti diabetic drugs for 3 months (metformin is obligatory)
  • -All on statin
  • -Stable medication uses past 3 months
  • -Able to give informed consent

排除标准

  • -Previous major cardiovascular event (e.g. AMI/stroke/TIA)
  • -GLP1 nor insulin
  • -antibiotic use in the past 3 months
  • -Probiotic or symbiotic usage
  • -Pregnant women,
  • -Chronic illness (including a known history of heart failure, renal failure (eGFR <30 ml/min), pulmonary disease, gastrointestinal disorders, or hematologic diseases), or other inflammatory diseases
  • -Active infection,
  • -Previous intestinal (e.g., bowel resection/reconstruction) surgery
  • -Smoking (can also influence microbiota)
  • -Vegetarian diet (since they have different microbiota)
  • ->6 alcohol units per day or >14 alcohol units per week
  • -Active malignancy
  • -HbA1c >9% (75mmol/mol)
  • -The subject is already involved in a clinical trial

研究者

发起方
/A

相似试验